Evidence map›Paper›PMID 31936301›Full record

ArticleInternational journal of molecular sciences2020

Characterization in Dual Activation by Oxaliplatin, a Platinum-Based Chemotherapeutic Agent of Hyperpolarization-Activated Cation and Electroporation-Induced Currents.

Wei-Ting Chang, Zi-Han Gao, Shih-Wei Li, Ping-Yen Liu, Yi-Ching Lo, Sheng-Nan Wu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Modulation ofInternational journal of molecular sciences · 2025
    Article
  2. Review
  3. Cannabidiol Modulates M-Type KBiomedicines · 2023
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Editorial to the Special Issue "Electrophysiology".International journal of molecular sciences · 2021
    Article
  9. Article
  10. Article
  11. Effectiveness in the Block by Honokiol, a Dimerized Allylphenol fromInternational journal of molecular sciences · 2020
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei-Ting ChangDivision of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan 71004, Taiwan.
Zi-Han GaoDepartment of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan.
Shih-Wei LiDepartment of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan.
Ping-Yen LiuInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Yi-Ching LoDepartment of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Sheng-Nan WuDepartment of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin (OXAL) is regarded as a platinum-based anti-neoplastic agent. However, its perturbations on membrane ionic currents in neurons and neuroendocrine or endocrine cells are largely unclear, though peripheral neuropathy has been noted during its long-term administration. In this study, we investigated how the presence of OXAL and other related compounds can interact with two types of inward currents; namely, hyperpolarization-activated cation current (

Indexed as

AnimalsCationsElectroporationHumansHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsMiceNeoplasmsNeuroendocrine CellsOxaliplatinSensory Receptor CellsCationsHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsOxaliplatinhyperpolarization-activated cation currentmembrane electroporation-induced currentolfactory neuronoxaliplatinpituitary cell

Identifiers

PMID31936301
PMCPMC7014111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.